A proteome-scale map of the human interactome network.Rolland T., Tasan M., Charloteaux B., Pevzner S.J., Zhong Q., Sahni N., Yi S., Lemmens I., Fontanillo C.[...], Vidal M.View abstractCategoriesInteractionSourceIntAct: Q8TF42PubMedEurope PMCCell 159:1212-1226 (2014)Mapped to99+
The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines.Charlaftis N., Suddason T., Wu X., Anwar S., Karin M., Gallagher E.View abstractCategoriesInteractionSourceIntAct: Q8TF42PubMedEurope PMCEMBO J. 33:2581-2596 (2014)Cited in1Mapped to99+
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.Li J., Bennett K., Stukalov A., Fang B., Zhang G., Yoshida T., Okamoto I., Kim J.Y., Song L.[...], Haura E.B.View abstractCategoriesInteractionSourceIntAct: Q8TF42PubMedEurope PMCMol Syst Biol 9:705-705 (2013)Mapped to99+
Charting the molecular network of the drug target Bcr-Abl.Brehme M., Hantschel O., Colinge J., Kaupe I., Planyavsky M., Kocher T., Mechtler K., Bennett K.L., Superti-Furga G.View abstractCategoriesInteractionSourceIntAct: Q8TF42PubMedEurope PMCProc Natl Acad Sci U S A 106:7414-7419 (2009)Mapped to91
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., Mathieson T., Perrin J., Raida M.[...], Drewes G.View abstractCategoriesInteractionSourceIntAct: Q8TF42PubMedEurope PMCNat Biotechnol 25:1035-1044 (2007)Mapped to99+